SOHO 2022 | Approaches to treating elderly patients with ALL: the role of TKIs and antibody therapies
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the challenges of treating elderly patients with acute lymphoblastic leukemia (ALL) and approaches to overcome these challenges. Dr Luskin first discusses options for patients with Philadelphia chromosome positive (Ph+) ALL, including tyrosine kinase inhibitors (TKIs), and then goes on to discuss options for patients with Ph negative (Ph-) disease, drawing focus on the role of antibody therapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
